` 2160 (Microport Cardioflow Medtech Corp) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

2160
vs
Hang Seng (Hong Kong)

Over the past 12 months, has underperformed Hang Seng (Hong Kong), delivering a return of -6% compared to the Hang Seng (Hong Kong)'s 28% growth.

Stocks Performance
2160 vs Hang Seng (Hong Kong)

Loading

Performance Gap
2160 vs Hang Seng (Hong Kong)

Loading
2160
Hang Seng (Hong Kong)
Difference

Performance By Year
2160 vs Hang Seng (Hong Kong)

Loading
2160
Hang Seng (Hong Kong)
Add Stock

Competitors Performance
Microport Cardioflow Medtech Corp vs Peers

Hang Seng (Hong Kong)
2160
ABT
ISRG
BSX
SYK
Add Stock

Microport Cardioflow Medtech Corp
Glance View

Market Cap
2.2B HKD
Industry
Health Care

MicroPort CardioFlow Medtech Corp. operates as a holding company with interest in developing medical devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-02-04. The firm is mainly engaged in the development and commercialization of transcatheter and surgical solutions for valvular heart diseases. The firm's main products include the first-generation transcatheter aortic heart valve implantation (TAVI) product VitaFlow and the second-generation TAVI product VitaFlow II. The firm mainly conducts business within the domestic market.

Intrinsic Value
1.76 HKD
Undervaluation 48%
Intrinsic Value
Price
Back to Top